Danaher Corporation announced a quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to shareholders recorded as of September 30, 2026. This dividend reflects Danaher's ongoing commitment to returning value to its investors. As a leading life sciences and diagnostics company, Danaher continues to focus on innovation and operational excellence to improve human health globally. Investors can expect this steady dividend as part of Danaher's financial strategy moving forward.
Danaher Corporation has a market cap of $142.88 billion as of September 16, 2026, 03:25 WIB, highlighting its significant presence in the health sector. The stock price on Pluang is USD 209.29, showing a 2.95% increase over the past day. Its dividend yield stands at 0.79%, indicating a steady return for shareholders as the company continues its financial strategy.
Danaher reported strong Q3 results with revenue up 8.3% to $6.55 billion and adjusted EPS of $2.11, surpassing analyst estimates. Growth was driven by the Biotechnology and Diagnostics segments despite challenges from changing respiratory test demand...
Danaher Corporation reported strong Q3 earnings with revenue up 8.3% year-over-year to $6.55 billion and adjusted EPS of $2.11, driven by growth in its Diagnostics segment. However, challenges remain from volatile respiratory revenue and pricing pres...
Danaher Corporation reported Q3 results showing an 8.3% year-over-year revenue increase, primarily driven by acquisitions and tariff refunds rather than organic growth. The company achieved an adjusted operating margin of 29%, surpassing guidance, bu...
Danaher reported Q3 2026 earnings per share of $2.11, surpassing analyst estimates of $1.92, although revenue slightly missed expectations at $6.55 billion versus $6.56 billion forecast. The company highlighted improving customer demand and faster co...
Danaher Corporation reported strong Q3 2026 results with net earnings rising 34.5% year-over-year to $1.2 billion, or $1.71 per diluted share. Revenues increased 8.5% to $6.6 billion, driven by core growth excluding respiratory revenue. The company r...
